New evidence added to the literature that paramagnetic rim lesions (PRLs) may be a biomarker of disability accumulation in ...

The Multiple Sclerosis Treatment Optimization Program (MSTOP) was motivated by research showing that Black and Hispanic ...

Neurology Live ® and the Consortium of Multiple Sclerosis Centers (CMSC) are pleased to announce the 2025 Giants of Multiple ...

Biogen’s CEO Chris Vibacher said ‘a new Biogen’ is emerging following the end of its multiple sclerosis treatments heyday.

According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug ...

Shares of Immunic (NASDAQ:IMUX) lost ~22% in the premarket on Wednesday after the immunology-focused biotech posted data from ...

Sales of multiple sclerosis drugs such as Tecfidera fell 11% to $953 million. Sales of rare disease drugs, including ...

The company cited topline data from its CALLIPER trial, which enrolled over 450 patients with primary progressive multiple sclerosis (PPMS ... the study drug caused a 20% reduction in the relative ...

Broad rim lesions, which have wider rims of immune cells, are associated with faster disease progression in MS, per a study.

Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped ...

(Reuters) - Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped offset declining sales of its multiple sclerosis medicines.

NJ joined 15 other states that force insurers to pay for biomarker tests in which specimens are examined for telltale signs of a disease or condition ...